Pulmocide raised $92 million in Series C funds in May 2021 to fund a registration program for opelconazole in patients with invasive pulmonary aspergillosis who have failed prior therapy.
Pulmocide Ltd. (“the Company”), a late-stage biopharmaceutical company focused on the development and commercialization of transformational therapies for patients with severe pulmonary diseases, today announced that the US Food and Drug Administration (FDA) has granted Orphan Drug, Fast Track and Qualified Infectious Disease Product designations for opelconazole (PC945) for the treatment of invasive pulmonary aspergillosis (IPA).
The full text of the press release can be found here.